Aggarwal R

References (3)

Title : Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer - Aggarwal_2026_J.Immunother.Cancer_14_
Author(s) : Aggarwal R , Zhang J , Monk P , Zhu X , Jones R , Linch M , Costin D , de Bono J , Karsh LI , Petrylak DP , Zhang L , Deshpande R , Borderies P , Huang J , O'Neill V , Donkor M , Tagawa S
Ref : J Immunother Cancer , 14 : , 2026
Abstract :
PubMedSearch : Aggarwal_2026_J.Immunother.Cancer_14_
PubMedID: 42114950

Title : Therapeutic potential of morpholine-based compounds in neurodegenerative diseases: SAR insights and analysis - Kumar_2025_Future.Med.Chem__1
Author(s) : Kumar S , Bishnoi P , Chauhan N , Kumar P , Aggarwal R
Ref : Future Med Chem , :1 , 2025
Abstract :
PubMedSearch : Kumar_2025_Future.Med.Chem__1
PubMedID: 40485213

Title : Vision on Synthetic and Medicinal Facets of 1,2,4-Triazolo[3,4-b][1,3,4]thiadiazine Scaffold - Aggarwal_2022_Top.Curr.Chem.(Cham)_380_10
Author(s) : Aggarwal R , Hooda M , Kumar P , Sumran G
Ref : Top Curr Chem (Cham) , 380 :10 , 2022
Abstract :
PubMedSearch : Aggarwal_2022_Top.Curr.Chem.(Cham)_380_10
PubMedID: 35122161